书信:低剂量的肝素.

Same author

Long-term benefit of thrombolytic therapy in patients with pulmonary embolism.

Vascular medicine (London, England)·2000

Same author

Platelet activation with unfractionated heparin at therapeutic concentrations and comparison with low-molecular-weight heparin and with a direct thrombin inhibitor.

Circulation·1999

Same author

Interventional use of plasminogen activators in central nervous system diseases.

The Medical clinics of North America·1998

Same author

A comparison of recombinant urokinase with vascular surgery as initial treatment for acute arterial occlusion of the legs. Thrombolysis or Peripheral Arterial Surgery (TOPAS) Investigators.

The New England journal of medicine·1998

Same author

Thrombolysis or peripheral arterial surgery: phase I results. TOPAS Investigators.

Journal of vascular surgery·1996

Same author

Clinical studies with the new glycosylated recombinant prourokinase.

Journal of vascular and interventional radiology : JVIR·1995

Same journal

Assisted dying and the silencing of medicine's next generation.

Lancet (London, England)·2026

Same journal

Linguistic pragmatism: a woman with progressive abdominal pain in Thailand.

Lancet (London, England)·2026

Same journal

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

Lancet (London, England)·2026

Same journal

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Lancet (London, England)·2026

Same journal

Research priorities for characterising Bundibugyo virus.

Lancet (London, England)·2026

Same journal

Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.

Lancet (London, England)·2026

相关实验视频

书信:低剂量的肝素.

相关概念视频

Long-term benefit of thrombolytic therapy in patients with pulmonary embolism.

Platelet activation with unfractionated heparin at therapeutic concentrations and comparison with low-molecular-weight heparin and with a direct thrombin inhibitor.

Interventional use of plasminogen activators in central nervous system diseases.

A comparison of recombinant urokinase with vascular surgery as initial treatment for acute arterial occlusion of the legs. Thrombolysis or Peripheral Arterial Surgery (TOPAS) Investigators.

Thrombolysis or peripheral arterial surgery: phase I results. TOPAS Investigators.

Clinical studies with the new glycosylated recombinant prourokinase.

Assisted dying and the silencing of medicine's next generation.

Linguistic pragmatism: a woman with progressive abdominal pain in Thailand.

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Research priorities for characterising Bundibugyo virus.

Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.

相关实验视频

书信:低剂量的肝素.

相关概念视频

相关文章

Long-term benefit of thrombolytic therapy in patients with pulmonary embolism.

Platelet activation with unfractionated heparin at therapeutic concentrations and comparison with low-molecular-weight heparin and with a direct thrombin inhibitor.

Interventional use of plasminogen activators in central nervous system diseases.

A comparison of recombinant urokinase with vascular surgery as initial treatment for acute arterial occlusion of the legs. Thrombolysis or Peripheral Arterial Surgery (TOPAS) Investigators.

Thrombolysis or peripheral arterial surgery: phase I results. TOPAS Investigators.

Clinical studies with the new glycosylated recombinant prourokinase.

Assisted dying and the silencing of medicine's next generation.

Linguistic pragmatism: a woman with progressive abdominal pain in Thailand.

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Research priorities for characterising Bundibugyo virus.

Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.